Therapeutic antibody against phosphorylcholine preserves coronary function and attenuates vascular F-18-FDG uptake in atherosclerotic mice

Author(s):
Stahle, M.; Silvola, J.M.U.; Hellberg, S.; Vries, M. de; Quax, P.H.A. (0000-0002-6853-5760); Kroon, J.; Rinne, P.; Jong, A. de; Liljenback, H.; Savisto, N.; Wickman, A.; Stroes, E.S.G.; Yla-Herttuala, S.; Saukko, P.; Abrahamsson, T.; Pettersson, K.; Knuuti, J.; Roivainen, A.; Saraste, A.
Published
2020
Publication type
Article / Letter to editor

Abstract

This study showed that treatment with a therapeutic monoclonal immunoglobutin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of F-18-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

atherosclerosiscoronary flow reserveinflammationF-18-fluorodeozyglucose positron emission tomographyphosphorylcholine
Date issued
2020-04-01
Language
English
Publisher
ELSEVIER SCIENCE INC
Is part of
JACC: Basic to Translational Science (2020), Vol. 5, no. 4, p. 360-373
hdl
1887/3185267
doi
10.1016/j.jacbts.2020.01.008